I need to say this clearly before anything else: research peptides are not FDA-approved, and this page is not encouraging anyone to use them.
The FDA approval process exists for good reasons. It verifies safety, efficacy, purity, and manufacturing consistency through years of rigorous clinical trials. When Novo Nordisk spent over a decade and billions of dollars developing semaglutide, they earned the right to that investment through a process designed to protect patients. Wegovy and Ozempic went through Phase I, II, and III trials involving tens of thousands of participants. That data is why your doctor can prescribe them with confidence. Research peptides have none of that — no clinical oversight, no manufacturing standards, no purity guarantees, no recourse if something goes wrong.
Research peptides are cheap for a reason. They skip every safeguard the pharmaceutical system was built to enforce. There’s no FDA inspector visiting the lab. No batch consistency requirements. No adverse event reporting system. The “99% purity” on a certificate of analysis is only as trustworthy as the vendor behind it — and in an industry where seven companies got raided in a single week last June, that trust has limits.
Everything else on this site — every article about GLP-1 therapy, menstrual cycles, PCOS, body composition — is about doing this right, under the supervision of a real doctor prescribing FDA-approved medications. That is always my recommendation. Telehealth has made access easier than ever. If you can get a prescription, get a prescription. Full stop.
That said, I’m a journalist, and I’d be ignoring reality if I pretended the research peptide market didn’t exist. Branded GLP-1 medications cost $900-1,300/month without insurance. Prior authorization denials are routine. Millions of people are priced out of the legitimate system. This page documents the vendor landscape as it exists — not as a shopping guide, but because accurate information is better than no information. Nothing below should be interpreted as a recommendation to purchase or use research peptides for any purpose other than legitimate scientific research.
How I Evaluate Vendors
Four things matter. Everything else is marketing.
Third-party testing. Not “we test our products” — independent, named laboratory analysis with batch-specific certificates of analysis (COAs) you can actually verify. HPLC purity testing at minimum. Mass spectrometry confirmation is better. If a vendor won’t show you the COA for the specific batch you’re buying, walk away.
Regulatory history. Has the FDA sent them a warning letter? Have they been raided? Is the owner under indictment? This industry has seen criminal prosecutions, forced shutdowns, and asset seizures in the past 18 months. History matters.
Consistency. Anyone can send one clean batch. The question is whether batch 47 is as pure as batch 1. Long operating history and consistent COA publication matter more than a single impressive test result.
Payment and shipping. Most mainstream payment processors won’t touch peptide vendors. The ones still accepting credit cards are either very large (grandfathered in) or using workarounds that could disappear tomorrow. Crypto-only isn’t a red flag in this industry — it’s the norm. Shipping speed and packaging quality vary wildly.
The Major Vendors in 2026
This is not a ranking. I’m listing the vendors that come up most often in community discussions, in my research, and in reader questions. Inclusion is not endorsement — I’m documenting the landscape.
Peptide Sciences
The market leader and the name everyone knows. Operating since approximately 2012, based in Torrance, California. Estimated $7.4 million in monthly revenue. They’ve built their reputation on longevity and product range — over 100 SKUs covering research peptides, proteins, and cosmetic peptides.
Evolve Peptides
A very new entrant — launched January 2025. Aggressive pricing with heavy GLP-1 focus. The permanent sale pricing (30-45% “discounts” that never end) is a common marketing tactic in this space that I find mildly irritating but not disqualifying.
Testing: Claims third-party testing, limited COA publication history. Pricing: Budget — among the lowest in the market. Payment: Cryptocurrency. Regulatory: Too new for enforcement history. Website: evolvepeptides.com
Panda Peptides
A newer entrant, launched in 2025, with a clear focus on GLP-1 compounds. What I find worth noting here: they publish Janoshik COAs for every batch, which is a more rigorous independent lab than what most budget vendors use. The pricing is genuinely competitive — not “permanent 40% off” theater, just straightforward budget pricing. They also use eCheck and cryptocurrency, which suggests they’re not relying on workarounds that could disappear overnight. For women specifically, their product descriptions are written in plain language without the bro-culture framing that dominates most of this space. Still newer, so less history to evaluate — but the fundamentals are right.
Testing: Independent third-party (Janoshik), batch-specific COAs published. Pricing: Budget — competitive pricing without manufactured discount gimmicks. Payment: Cryptocurrency, eCheck. Regulatory: No public FDA enforcement actions. Website:
Pure Rawz
One of the broadest catalogs in the space — peptides, SARMs, nootropics, and more. Operating since approximately 2015. Mixed reputation in community discussions, with some BBB complaints on record.
Testing: Third-party COAs available. Pricing: Mid-range. Payment: Cryptocurrency, Venmo. Regulatory: No public FDA enforcement actions, but BBB complaints exist. Website: purerawz.co
Core Peptides
A mid-tier vendor with a standard catalog. Less prominent in community discussions than the names above, but operational and serving the market.
Testing: Testing claimed, COA availability varies. Pricing: Mid-range. Payment: Cryptocurrency. Regulatory: No public FDA enforcement actions. Website: corepeptides.com
Vendors That No Longer Exist
Worth documenting because it tells you something about this industry’s volatility:
Amino Asylum — Shut down in June 2025 FDA raids in Florida, along with six other companies. Paradigm Peptides — Owner pled guilty in December 2025 to federal charges. Sentencing scheduled for June 2026. Science.bio — Closed voluntarily in January 2026. Was widely considered one of the most transparent vendors in the space.
The pattern is clear: this market is consolidating under regulatory pressure. The vendors still operating in 2026 are either very careful, very large, or haven’t been caught yet. Keep that context in mind.
Quick Comparison
For the GLP-1 researchers who want the bottom line:
| Vendor | Price Tier | Third-Party COA | Payment | Operating Since | Regulatory Notes |
|---|---|---|---|---|---|
| Peptide Sciences | Premium | Yes | Cards | ~2012 | No public enforcement |
| Swiss Chems | Budget | Yes | Crypto | ~2016 | FDA warning letter (Dec 2024) |
| Biotech Peptides | Mid-range | Yes | Cards, crypto | ~2015 | No public enforcement |
Pricing tiers are relative to market averages as of February 2026 and change frequently. Inclusion in this table does not constitute endorsement or a recommendation to purchase. Research peptides are sold for laboratory and research use only and are not FDA-approved for human consumption.
Get the prescription if you can. Seriously. I know I keep saying it, but supervised medical care with FDA-approved medications is objectively better than self-directed research with unregulated compounds. The cost barrier is real and I won’t pretend otherwise — but explore every option (insurance appeals, manufacturer coupons, telehealth programs) before going the research route.
If you’ve exhausted those options and you’re sourcing research peptides: prioritize testing transparency above everything else. A vendor who publishes batch-specific, independently verified COAs is telling you they’re willing to be held accountable. A vendor who says “trust us” is telling you something too.
I’ll keep this page updated as the landscape shifts — and in this industry, it shifts constantly.
Charlotte Reed is a health journalist covering GLP-1 therapy and women’s health. This page is updated quarterly. Last update: February 2026. For editorial standards and conflict disclosures, see our Editorial Policy and Affiliate Disclosure.